The British-Swedish pharmaceutical group AstraZeneca said on Friday it would seek regulatory approval for an antibody drug after a study showed strong efficacy in preventing symptomatic COVID-19.
This new treatment will significantly reduce the risk of developing COVID-19 symptoms and will offer as well a potential new alternative to vaccines for people who refuse shots or for whom they aren’t effective.
This antibody treatment, whose code name is “AZD7442”, is a combination of two long-acting antibodies (LAAB), reducing the risk of developing symptomatic COVID-19 by 77%, according to results of the Phase III trial’s data.
“With these exciting results, AZD7442 could be an important tool in our arsenal to help people who may need more than a vaccine to return to their normal lives”, said Myron Levin, Professor of Pediatrics and Medicine, University of Colorado School of Medicine, US, and principal investigator on the trial, according to AstraZeneca’s website.
“We look forward to sharing further data from the AZD7442 Phase III clinical trial program later this year,” said Mene Pangalos, the executive vice-president, BioPharmaceuticals R&D, on AstraZeneca’s website.
AstraZeneca will prepare the regulatory submission of this new treatment data to health authorities for potential emergency use authorization or conditional approval of AZD7442 as well as the results of the trials will be submitted in order to be published in a peer-reviewed medical journal and presented at a forthcoming medical meeting, according to the same source.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.